Anti-stroke biologics: from recombinant proteins to stem cells and organoids
The use of biologics in various diseases has dramatically increased in recent years. Stroke, a cerebrovascular disease, is the second most common cause of death, and the leading cause of disability with high morbidity worldwide. For biologics applied in the treatment of acute ischaemic stroke, altep...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
|
| Series: | Stroke and Vascular Neurology |
| Online Access: | https://svn.bmj.com/content/early/2024/01/29/svn-2023-002883.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846171748728307712 |
|---|---|
| author | Shu-Na Wang Chao-Yu Miao Zhi Wang Zhu-Wei Miao Si-Li Zheng |
| author_facet | Shu-Na Wang Chao-Yu Miao Zhi Wang Zhu-Wei Miao Si-Li Zheng |
| author_sort | Shu-Na Wang |
| collection | DOAJ |
| description | The use of biologics in various diseases has dramatically increased in recent years. Stroke, a cerebrovascular disease, is the second most common cause of death, and the leading cause of disability with high morbidity worldwide. For biologics applied in the treatment of acute ischaemic stroke, alteplase is the only thrombolytic agent. Meanwhile, current clinical trials show that two recombinant proteins, tenecteplase and non-immunogenic staphylokinase, are most promising as new thrombolytic agents for acute ischaemic stroke therapy. In addition, stem cell-based therapy, which uses stem cells or organoids for stroke treatment, has shown promising results in preclinical and early clinical studies. These strategies for acute ischaemic stroke mainly rely on the unique properties of undifferentiated cells to facilitate tissue repair and regeneration. However, there is a still considerable journey ahead before these approaches become routine clinical use. This includes optimising cell delivery methods, determining the ideal cell type and dosage, and addressing long-term safety concerns. This review introduces the current or promising recombinant proteins for thrombolysis therapy in ischaemic stroke and highlights the promise and challenges of stem cells and cerebral organoids in stroke therapy. |
| format | Article |
| id | doaj-art-80ea9d6f6d8b4d99a91a958b4c34c230 |
| institution | Kabale University |
| issn | 2059-8696 |
| language | English |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Stroke and Vascular Neurology |
| spelling | doaj-art-80ea9d6f6d8b4d99a91a958b4c34c2302024-11-10T12:35:08ZengBMJ Publishing GroupStroke and Vascular Neurology2059-869610.1136/svn-2023-002883Anti-stroke biologics: from recombinant proteins to stem cells and organoidsShu-Na Wang0Chao-Yu Miao1Zhi Wang2Zhu-Wei Miao3Si-Li Zheng4Department of Pharmacology, Second Military Medical University/ Naval Medical University, Shanghai, ChinaDepartment of Pharmacology, Second Military Medical University/ Naval Medical University, Shanghai, ChinaDepartment of Anesthesiology, Shanxi Provincial Peoples Hospital, Taiyuan, Shanxi, ChinaDepartment of Pharmacology, Second Military Medical University/ Naval Medical University, Shanghai, ChinaDepartment of Pharmacology, Second Military Medical University/ Naval Medical University, Shanghai, ChinaThe use of biologics in various diseases has dramatically increased in recent years. Stroke, a cerebrovascular disease, is the second most common cause of death, and the leading cause of disability with high morbidity worldwide. For biologics applied in the treatment of acute ischaemic stroke, alteplase is the only thrombolytic agent. Meanwhile, current clinical trials show that two recombinant proteins, tenecteplase and non-immunogenic staphylokinase, are most promising as new thrombolytic agents for acute ischaemic stroke therapy. In addition, stem cell-based therapy, which uses stem cells or organoids for stroke treatment, has shown promising results in preclinical and early clinical studies. These strategies for acute ischaemic stroke mainly rely on the unique properties of undifferentiated cells to facilitate tissue repair and regeneration. However, there is a still considerable journey ahead before these approaches become routine clinical use. This includes optimising cell delivery methods, determining the ideal cell type and dosage, and addressing long-term safety concerns. This review introduces the current or promising recombinant proteins for thrombolysis therapy in ischaemic stroke and highlights the promise and challenges of stem cells and cerebral organoids in stroke therapy.https://svn.bmj.com/content/early/2024/01/29/svn-2023-002883.full |
| spellingShingle | Shu-Na Wang Chao-Yu Miao Zhi Wang Zhu-Wei Miao Si-Li Zheng Anti-stroke biologics: from recombinant proteins to stem cells and organoids Stroke and Vascular Neurology |
| title | Anti-stroke biologics: from recombinant proteins to stem cells and organoids |
| title_full | Anti-stroke biologics: from recombinant proteins to stem cells and organoids |
| title_fullStr | Anti-stroke biologics: from recombinant proteins to stem cells and organoids |
| title_full_unstemmed | Anti-stroke biologics: from recombinant proteins to stem cells and organoids |
| title_short | Anti-stroke biologics: from recombinant proteins to stem cells and organoids |
| title_sort | anti stroke biologics from recombinant proteins to stem cells and organoids |
| url | https://svn.bmj.com/content/early/2024/01/29/svn-2023-002883.full |
| work_keys_str_mv | AT shunawang antistrokebiologicsfromrecombinantproteinstostemcellsandorganoids AT chaoyumiao antistrokebiologicsfromrecombinantproteinstostemcellsandorganoids AT zhiwang antistrokebiologicsfromrecombinantproteinstostemcellsandorganoids AT zhuweimiao antistrokebiologicsfromrecombinantproteinstostemcellsandorganoids AT silizheng antistrokebiologicsfromrecombinantproteinstostemcellsandorganoids |